Study Provides Insight Into Dual and Triple Therapy Options for Diabetes
Jun 20, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: David Clarke, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences
Danish study makes strong recommendations for diabetes pharmacotherapy beyond metformin, examining dual and triple therapy for type 2.
In the treatment of type 2 diabetes (T2D), the first-line option is typically straightforward, with metformin being the preferred first-line drug. However, when it comes to the second and third-line options for pharmacological treatment of T2D, that is where the preferred option becomes less clear. There are multiple drug classes to choose from and multiple drugs within those classes, making the potential combinations for dual and triple therapy overwhelming. Randomized controlled trials (RCT) provide evidence to guide clinicians in the selection of second and third-line treatments for T2D; for instance, the EMPA-REG OUTCOME trial showed that the sodium-glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin decreased the risk of cardiovascular mortality, thus making it a preferred treatment for T2D patients at risk for ASCVD events....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.